Trexquant Investment LP boosted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 147.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,656 shares of the company's stock after acquiring an additional 36,122 shares during the period. Trexquant Investment LP's holdings in Denali Therapeutics were worth $1,236,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of Denali Therapeutics in the fourth quarter worth $21,717,000. Vanguard Group Inc. increased its holdings in Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after buying an additional 843,996 shares during the period. Segall Bryant & Hamill LLC bought a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $5,891,000. Alliancebernstein L.P. increased its stake in Denali Therapeutics by 8.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock valued at $67,573,000 after acquiring an additional 268,378 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in Denali Therapeutics by 44.8% during the fourth quarter. Fisher Asset Management LLC now owns 792,499 shares of the company's stock valued at $16,151,000 after purchasing an additional 245,168 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.
Denali Therapeutics Trading Up 0.3 %
DNLI stock traded up $0.04 during trading on Tuesday, hitting $13.31. The company had a trading volume of 247,114 shares, compared to its average volume of 1,078,200. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The business has a 50-day moving average of $16.32 and a 200-day moving average of $21.66. The stock has a market cap of $1.93 billion, a PE ratio of -4.84 and a beta of 1.58.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. Research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have weighed in on DNLI. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Baird R W raised Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a research note on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price target on the stock. Finally, William Blair reiterated an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of "Buy" and an average target price of $37.57.
Read Our Latest Stock Report on Denali Therapeutics
About Denali Therapeutics
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
See Also
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
